Orchestra BioMed Holdings, Inc.
NASDAQ:OBIOBiotechnology
+$0.05 today
- Market cap
- $587.14M
- Beta
- 0.50
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.42
Volume 1.20M
Average 0.22M
OBIO Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Orchestra BioMed Holdings, Inc.NASDAQ: OBIO
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $22.35M (cash outflow) rose 33.6% year over year, ahead of the +1.1% change in trailing-twelve-month free cash flow. Sequentially, it rose 870.6% from the prior quarter. Over 3 fiscal years it compounded at +18.3% a year.
Context
- Free cash flow amounted to 147.7% of revenue in FY2025, down 1779.8 pp from a year earlier.
- Free cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +33.6% holds above the trailing-twelve-month pace of +1.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (49.45M) USD
- Year-over-year change
- +2.7%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (49.45M) | +2.7% |
| FY2024 | 2024-12-31 | (50.85M) | -10.0% |
| FY2023 | 2023-12-31 | (46.21M) | -54.6% |
| FY2022 | 2022-12-31 | (29.88M) | -51.7% |
| FY2021 | 2021-12-31 | (19.7M) | — |
Free Cash Flow vs competitors
How OBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1.1% is the 6th highest of 11, against a peer median of -6.0%.
- Free cash flow amounts to 168.3% of revenue for OBIO, versus a peer median of 695.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $101.64M USD | -28.6% | +4.9% | 907.3% | |
| FY2025 | €101.22M EUR | +17.3% | +30.6% | 2257.9% | |
| LTM Mar 2026 | $79.46M USD | -43.9% | -35.9% | 142.2% | |
| LTM Mar 2026 | $66.98M USD | +12.6% | -12.8% | 483.3% | |
| LTM Mar 2026 | $64.63M USD | -24.7% | -18.0% | 28725.3% | |
| LTM Mar 2026 | $63.05M USD | +56.6% | +28.6% | — | |
| LTM Mar 2026 | $59.69M USD | +14.1% | +24.2% | 101172.9% | |
| LTM Mar 2026 | $55.08M USD | +1.1% | +18.3% | 168.3% | |
| LTM Mar 2026 | $43.78M USD | -58.6% | -13.4% | 261.8% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $32.16M USD | +26.8% | +26.5% | — |
| LTM Mar 2026 | $9.61M USD | -88.3% | -28.2% | 13.9% | |
| Peer median (excluding OBIO) | — | -6.0% | -4.0% | 695.3% | |
Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (23.01M) | (33.61M) | (49.12M) | (61.02M) | (52.7M) |
| Depreciation & Amortization | 181K | 222K | 287K | 308K | 327K |
| Deferred Income Tax | 288K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 302K | 3.41M | 7.63M | 10.62M | 11.98M |
| Change in Working Capital | 2.6M | (451K) | (3.31M) | (765K) | (10.37M) |
| Accounts Receivables | 47K | 25K | (3K) | 22K | (3K) |
| Inventory | 1K | (208K) | 131K | (28K) | (137K) |
| Accounts Payables | 1.08M | 0 | 145K | 2.97M | 0 |
| Other Working Capital | 1.47M | (268K) | (3.58M) | (3.73M) | (10.23M) |
| Other Non-Cash Items | 217K | 1.14M | (1.61M) | 308K | 1.81M |
| Operating Cash Flow | (19.43M) | (29.29M) | (46.13M) | (50.56M) | (48.96M) |
| Capital Expenditures | (274K) | (591K) | (78K) | (289K) | (489K) |
| Acquisitions (Net) | (13.29M) | 0 | 0 | (602K) | 0 |
| Purchases of Investments | (213K) | (63.53M) | (142.03M) | (72.65M) | (76.31M) |
| Sales of Investments | 13.5M | 0 | 152.8M | 86.63M | 49.86M |
| Other Investing Activities | 13.29M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 13.02M | (64.12M) | 10.69M | 13.09M | (26.94M) |
| Debt Repayment | (4M) | 3.55M | (10.85M) | 15M | 17.91M |
| Common Stock Issued | 7K | 109.83M | 254K | 15.04M | 71.97M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7K | (10.13M) | 56.81M | (864K) | (1.55M) |
| Financing Cash Flow | (3.99M) | 103.26M | 46.22M | 29.17M | 88.33M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (10.41M) | 9.85M | 10.78M | (8.3M) | 12.43M |
| Free Cash Flow | (19.7M) | (29.88M) | (46.21M) | (50.85M) | (49.45M) |
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
Intrinsic Alpha fair value
Locked
Current Price
$7.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.